The more interesting hit molecules discovered by the combined screening algorithm were three marketed drugs (Figure S8), two being CNS-acting molecules and one non-CNS acting drug: desvenlafaxine, the main metabolite of venlafaxine (SNRI antidepressant), paliperidone, the active metabolite of risperidone (antipsychotic dopamine D2 receptor antagonist and serotonin 5-HT2A receptor antagonist), febuxostat (xanthine-oxidase inhibitor for gout treatment). This evidence concerns the gene DRD2 and gout.